AstraZeneca PLC
http://www.astrazeneca.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AstraZeneca PLC
BioNTech Ramps Up Spending To Launch 10 Pivotal Cancer Studies In 2024
As COVID-19 vaccine sales decline, the company is investing billions in a diverse oncology pipeline including antibody drug conjugates, immunotherapy and cancer vaccines
Synthetic Biology Matures, Promising Affordable And Personalized Treatments
Advances in synthetic biology are moving biopharma closer to a world where treatments can be tailored while remaining cost-effective.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Drug Promotion: Sponsors Are Running Afoul Of US FDA’s CFL Guidance
Recent Office of Prescription Drug Promotion enforcement letters provide several learnings, including the need to be aware of a product’s regulatory history and competitive landscape when developing promotions that are consistent with FDA-labeling, experts said.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Alexion Pharmaceuticals Inc.
- Almirall Sofotec
- AlphaCore Pharma
- Amplimmune, Inc.
- Ardea Biosciences, Inc.
- Arrow Therapeutics
- Aviron
- Cellective Therapeutics, Inc.
- Definiens
- IntraBiotics Pharmaceuticals, Inc.
- KuDOS Pharmaceuticals Ltd.
- Medimmune
- Novexel
- Neogene Therapeutics, Inc.
- Omthera Pharmaceuticals
- Pearl Therapeutics
- Spirogen Ltd.
- TeneoTwo, Inc.
- U.S. Bioscience
- Acerta Pharma
- ZS Pharma
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice